Campbell & CO Investment Adviser LLC

Position in GRFS — Grifols SA

CIK 1353570 BALTIMORE, MD

Position in GRFS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$512,060

-$358,742 QoQ

Shares Held

63,848

-31.4% QoQ

Ownership

0.025%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2020

11 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 0.ToString("F0")% None 100.ToString("F0")%

Healthcare · as of Mar 31, 2026

Campbell & CO Investment Adviser LLC holds $29,502,691 across 9 Drug Manufacturers - General names. GRFS ranks #8 (1.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	GILD	Gilead Sciences, Inc.	50,560	$7,046,547
2	LLY	ELI LILLY & Co	7,041	$6,476,100
3	NVS	Novartis AG	39,646	$6,055,926
4	AMGN	Amgen Inc	14,110	$4,964,603
5	BMY	Bristol Myers Squibb Co	29,424	$1,784,565
6	AZN	Astrazeneca PLC	8,338	$1,644,420
7	OGN	Organon & Co.	128,309	$768,570
8	GRFS	Grifols SA This page	63,848	$512,060

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$512,060	63,848	-31.4%	Shares	Sole	2026-05-15
2025-12-31	$870,802	93,134	-20.2%	Shares	Sole	2026-02-12
2025-09-30	$1,162,351	116,702	+6.6%	Shares	Sole	2025-10-28
2025-06-30	$989,554	109,464	+516.4%	Shares	Sole	2025-08-07
2025-03-31	$126,259	17,758	-91.7%	Shares	Sole	2025-05-14
2024-09-30	$1,907,672	214,828	+473.0%	Shares	Sole	2024-11-12
2024-06-30	$236,593	37,495	-29.0%	Shares	Sole	2024-08-13
2023-12-31	$610,483	52,810	+63.4%	Shares	Sole	2024-02-13
2023-03-31	$238,161	32,315	+2.4%	Shares	Sole	2023-05-11
2022-09-30	$194,465	31,569	+189.8%	Shares	Sole	2022-11-14
2020-06-30	$198,724	10,895	—	Shares	Sole	2020-07-29
No filing history on record for this holder in this stock.